The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma

SINCAN, Suat; SİNCAN, gulden; KARAKÖSE, Mediha Nur; erdem, fuat; Aksoz, Zekeriya

doi:10.4274/meandros.galenos.2023.74317

The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma

Suat SİNCAN, (Atatürk Üniversitesi Tıp Fakültesi Hastanesi, Aile Hekimliği Kliniği, Erzurum, Türkiye)

Gülden SİNCAN, (Atatürk Üniversitesi Tıp Fakültesi Hastanesi Hematoloji Kliniği, Erzurum, Türkiye)

Mediha Nur KARAKÖSE, (Atatürk Üniversitesi Tıp Fakültesi Hastanesi, Dahiliye Kliniği, Erzurum, Türkiye)

Zekeriya Aksoz, (Adıyaman Eğitim ve Araştırma Hastanesi Hematoloji Kliniği, Erzurum, Türkiye)

Fuat ERDEM (Atatürk Üniversitesi Tıp Fakültesi Hastanesi Hematoloji Kliniği, Erzurum, Türkiye)

Meandros Medical And Dental Journal

2 2

Yıl: 2023 Cilt: 24 Sayı: 2 Sayfa Aralığı: 166 - 174 Metin Dili: İngilizce DOI: 10.4274/meandros.galenos.2023.74317 İndeks Tarihi: 26-07-2023

The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma

Öz:

Objective: Increased inflammatory cells in the tumor microenvironment are important in the formation and progression of lymphomas. C-reactive protein (CRP) and procalcitonin (PCT) are biomarkers that can be used to detect infection and inflammation. We investigated the clinical significance of CRP and PCT levels in lymphoma cases. Materials and Methods: We evaluated 82 Hodgkin and 120 diffuse large B-cell lymphoma (DLBCL) cases. Pre- and post-treatment PCT and CRP values were compared. The relationship between pre-treatment CRP and PCT levels and response to chemotherapy treatment, disease stage, performance score, extranodal involvement, presence of bulky mass, and bone marrow involvement was determined. Results: In the Hodgkin lymphoma group, the CRP level was increased in 40 (48.8%) patients and the PCT level was increased in 16 (19.5%) patients. The CRP level was high in 36 (30%) cases and the PCT level was high in 34 (18.3%) cases in the DLBCL group. CRP and PCT levels were significantly lower after chemotherapy treatment in all of our cases compared to pretreatment (p<0.001, p<0.001, respectively). Conclusion: The decrease in CRP and PCT levels after chemotherapy treatment in our Hodgkin and DLBCL cases compared with pretreatment supports the role of inflammation in the pathogenesis. In addition, these parameters may contribute to the determination of prognosis.

Anahtar Kelime:

Lenfomalı Hastalarda Serum Prokalsitonin ve C-reaktif Protein Düzeylerinin Önemi

Öz:

Amaç: Fazla enflamatuvar hücrenin bulunduğu tümör mikro çevresi, lenfomaların oluşumunda ve ilerlemesinde önemlidir. C-reaktif protein (CRP) ve prokalsitonin (PCT), enfeksiyon ve enflamasyonu tespit etmek için kullanılabilen biyobelirteçlerdir. Biz lenfoma olgularında CRP ve PCT düzeylerinin klinik önemini araştırdık. Gereç ve Yöntemler: Seksen iki Hodgkin ve 120 diffüz büyük B-hücreli lenfoma olgusunu değerlendirdik. Tedavi öncesi ve sonrası PCT ve CRP değerleri karşılaştırıldı. Tedavi öncesi CRP ve PCT düzeyleri ile kemoterapi tedavisine yanıt, hastalık evresi, performans skoru, ekstranodal tutulum, hacimli kitle varlığı ve kemik iliği tutulumu arasındaki ilişki belirlendi. Bulgular: Hodgkin lenfoma grubunda 40 (%48,8) hastada CRP düzeyi, 16 (%19,5) hastada PCT düzeyi yüksek idi. Diffüz büyük B-hücreli lenfoma grubunda CRP düzeyi 36 (%30) olguda, PCT düzeyi 34 (%18,3) olguda yüksekti. CRP ve PCT düzeyleri kemoterapi tedavisi sonrası tüm olgularımızda tedavi öncesine göre anlamlı olarak düşüktü (sırasıyla p<0,001, p<0,001). Sonuç: Hogkin ve diffüz büyük B-hücreli lenfoma olgularımızda kemoterapi tedavisi sonrası CRP ve PCT düzeylerinin tedavi öncesine göre azalması inflamasyonun patogenezdeki rolünü desteklemektedir. Ayrıca bu parametreler prognozun belirlenmesinde de katkı sağlayabilir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: How hot is the link?. Biochem Pharmacol 2006; 72: 1605-21.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
3. Li F, Tiede B, Massagué J. Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007; 17: 3-14.
4. Makgoeng SB, Bolanos RS, Jeon CY, Weiss RE, Arah OA, Breen EC, et al. Markers of Immune Activation and Inflammation, and Non- Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies. JNCI Cancer Spectrum 2018; 2: pky082
5. Poppema S, Potters M, Emmens R, Visser L, van den Berg A. Immune reactions in classical Hodgkin’s lymphoma. Semin Hematol 1999; 36: 253-9.
6. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011; 29: 1812-26.
7. Schottenfeld D, Beebe-Dimmer J. Chronic Inflammation: A Common and Important Factor in the Pathogenesis of Neoplasia. CA Cancer J Clin 2006; 56: 69-83.
8. Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G, et al. Elevated serum IL-10 levels in diffuse large B–cell lymphoma: A mechanism of aberrant JAK2 activation. Blood 2012; 119: 2844-53.
9. Yeh ET. CRP as a mediator of disease. Circulation 2004; 109: II11-4.
10. Li S, Rong H, Guo Q, Chen Y, Zhang G, Yang J. Serum procalcitonin levels distinguish gram-negative bacterial sepsis from gram- positive bacterial and fungal sepsis. J Res Med Sci 2016; 21: 39-46.
11. Matzaraki V, Alexandraki KI, Venetsanou K, Piperi C, Myrianthefs P, Malamos N, et al. Evaluation of serum procalcitonin and interleukin-6 levels of liver metastasis. Clin Biochem 2007; 40: 336-42.
12. Zielinski CC, Preis P, Aiginger P, Eibl MM. Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin’s disease. J Cancer Res Clin Oncol 1985; 110: 65-70.
13. Legouffe E, Rodriguez C, Picgt MC, Richard B, Klein B, Rossi JF, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non-Hodgkin’s lymphoma. Leuk Lymphoma 1998; 31: 351-7.
14. Wieland A, Kerbl R, Berghold A, Schwinger W, Mann G, Urban C. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol 2003; 41: 21-5.
15. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 1984; 19: 193-8.
16. Cao Y, Shi YX, Chen JO, Tan YT, Cai YC, Luo HY, et al. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol 2012; 33: 1039-44.
17. Da Silveira da Rocha TM, Miranda Silva AL, Fortier SC, Chiattone CS. Evaluation correlates C-reactive protein with advanced stage Hodgkin’s lymphoma and response to treatment in a tertiary university hospital in Brazil. Rev Bras Hematol Hemoter 2015; 37: 242-6.
18. Haase R, Vilser C, Mauz-Körholz C, Hasenclever D, Kluge R, Ruschke K, et al. Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin’s lymphoma (HL). Klin Padiatr 2012; 224: 377-81.
19. Chaftari AM, Hachem R, Reitzel R, Jordan M, Jiang Y, Yousif A, et al. Role of Procalcitonin and Interleukin-6 in Predicting Cancer, and Its Progression Independent of Infection. PLoS One 2015; 10: 1-11.
20. Kawaguchi Y, Saito B, Nakata A, Matsui T, Sasaki Y, Shimada S, et al. Elevated C-reactive protein level is associated with poor prognosis in follicular lymphoma patients undergoing rituximab- containing chemotherapy. Int J Hematol 2020; 112: 341-8.

APA	SINCAN S, SİNCAN g, KARAKÖSE M, Aksoz Z, erdem f (2023). The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. , 166 - 174. 10.4274/meandros.galenos.2023.74317
Chicago	SINCAN Suat,SİNCAN gulden,KARAKÖSE Mediha Nur,Aksoz Zekeriya,erdem fuat The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. (2023): 166 - 174. 10.4274/meandros.galenos.2023.74317
MLA	SINCAN Suat,SİNCAN gulden,KARAKÖSE Mediha Nur,Aksoz Zekeriya,erdem fuat The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. , 2023, ss.166 - 174. 10.4274/meandros.galenos.2023.74317
AMA	SINCAN S,SİNCAN g,KARAKÖSE M,Aksoz Z,erdem f The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. . 2023; 166 - 174. 10.4274/meandros.galenos.2023.74317
Vancouver	SINCAN S,SİNCAN g,KARAKÖSE M,Aksoz Z,erdem f The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. . 2023; 166 - 174. 10.4274/meandros.galenos.2023.74317
IEEE	SINCAN S,SİNCAN g,KARAKÖSE M,Aksoz Z,erdem f "The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma." , ss.166 - 174, 2023. 10.4274/meandros.galenos.2023.74317
ISNAD	SINCAN, Suat vd. "The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma". (2023), 166-174. https://doi.org/10.4274/meandros.galenos.2023.74317

APA	SINCAN S, SİNCAN g, KARAKÖSE M, Aksoz Z, erdem f (2023). The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. Meandros Medical And Dental Journal, 24(2), 166 - 174. 10.4274/meandros.galenos.2023.74317
Chicago	SINCAN Suat,SİNCAN gulden,KARAKÖSE Mediha Nur,Aksoz Zekeriya,erdem fuat The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. Meandros Medical And Dental Journal 24, no.2 (2023): 166 - 174. 10.4274/meandros.galenos.2023.74317
MLA	SINCAN Suat,SİNCAN gulden,KARAKÖSE Mediha Nur,Aksoz Zekeriya,erdem fuat The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. Meandros Medical And Dental Journal, vol.24, no.2, 2023, ss.166 - 174. 10.4274/meandros.galenos.2023.74317
AMA	SINCAN S,SİNCAN g,KARAKÖSE M,Aksoz Z,erdem f The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. Meandros Medical And Dental Journal. 2023; 24(2): 166 - 174. 10.4274/meandros.galenos.2023.74317
Vancouver	SINCAN S,SİNCAN g,KARAKÖSE M,Aksoz Z,erdem f The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. Meandros Medical And Dental Journal. 2023; 24(2): 166 - 174. 10.4274/meandros.galenos.2023.74317
IEEE	SINCAN S,SİNCAN g,KARAKÖSE M,Aksoz Z,erdem f "The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma." Meandros Medical And Dental Journal, 24, ss.166 - 174, 2023. 10.4274/meandros.galenos.2023.74317
ISNAD	SINCAN, Suat vd. "The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma". Meandros Medical And Dental Journal 24/2 (2023), 166-174. https://doi.org/10.4274/meandros.galenos.2023.74317